A phase I trial of intranasal Moli1901 for cystic fibrosis
PL Zeitlin, MP Boyle, WB Guggino, L Molina - Chest, 2004 - Elsevier
Background The peptide drug Moli1901 activates an alternative chloride channel that is
present in cystic fibrosis (CF) nasal and airway epithelia. Doing so bypasses the
dysfunctional CF transmembrane regulator. Study objective To determine whether intranasal
Moli1901 is safe, tolerable, and will induce chloride transport in healthy volunteers and CF
subjects. Design A single-blind (to the participant), randomized, placebo-controlled, dose-
escalation study of intranasal Moli1901 was performed in four healthy non-CF participants …
present in cystic fibrosis (CF) nasal and airway epithelia. Doing so bypasses the
dysfunctional CF transmembrane regulator. Study objective To determine whether intranasal
Moli1901 is safe, tolerable, and will induce chloride transport in healthy volunteers and CF
subjects. Design A single-blind (to the participant), randomized, placebo-controlled, dose-
escalation study of intranasal Moli1901 was performed in four healthy non-CF participants …